Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CON Stock Forecast 2026-2027
$24.16
Current Price
$3.10B
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CON Price Targets
+32.5%
To High Target of $32.00
+24.2%
To Median Target of $30.00
+15.9%
To Low Target of $28.00
CON Price Momentum
+6.6%
1 Week Change
+10.2%
1 Month Change
+12.9%
1 Year Change
+22.8%
Year-to-Date Change
-3.4%
From 52W High of $25.00
+30.3%
From 52W Low of $18.55
📊 TOP ANALYST CALLS
Did CON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Concentra is one of their latest high-conviction picks.
Latest CON Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CON has a bullish consensus with a median price target of $30.00 (ranging from $28.00 to $32.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $24.16, the median forecast implies a 24.2% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jamie Perse at Goldman Sachs, projecting a 32.5% upside. Conversely, the most conservative target is provided by Stephen Baxter at Wells Fargo, suggesting a 15.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CON Analyst Ratings
7
Buy
0
Hold
0
Sell
CON Price Target Range
Low
$28.00
Average
$30.00
High
$32.00
Current: $24.16
Latest CON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $28.00 |
| Feb 2, 2026 | RBC Capital | Ben Hendrix | Outperform | Maintains | $31.00 |
| Sep 18, 2025 | JP Morgan | Benjamin Rossi | Overweight | Assumes | $31.00 |
| Mar 19, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $30.00 |
| Mar 12, 2025 | Wells Fargo | Overweight | Maintains | $25.00 | |
| Jan 23, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $30.00 |
| Jan 23, 2025 | B of A Securities | Joanna Gajuk | Buy | Maintains | $25.00 |
| Dec 16, 2024 | B of A Securities | Buy | Upgrade | $N/A | |
| Nov 4, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $30.00 |
| Oct 7, 2024 | B of A Securities | Joanna Gajuk | Neutral | Downgrade | $24.00 |
| Aug 20, 2024 | RBC Capital | Ben Hendrix | Outperform | Initiates | $33.00 |
| Aug 19, 2024 | Goldman Sachs | Jamie Perse | Buy | Initiates | $32.00 |
| Aug 19, 2024 | JP Morgan | Lisa Gill | Overweight | Initiates | $29.00 |
| Aug 19, 2024 | Truist Securities | David Macdonald | Buy | Initiates | $29.00 |
| Aug 19, 2024 | Deutsche Bank | Justin Bowers | Buy | Initiates | $29.00 |
| Aug 19, 2024 | Wells Fargo | Overweight | Initiates | $27.00 | |
| Aug 19, 2024 | Mizuho | Ann Hynes | Outperform | Initiates | $28.00 |
| Aug 19, 2024 | B of A Securities | Joanna Gajuk | Buy | Initiates | $30.50 |
Concentra Group Holdings Parent Inc (CON) Competitors
The following stocks are similar to Concentra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Concentra Group Holdings Parent Inc (CON) Financial Data
Concentra Group Holdings Parent Inc has a market capitalization of $3.10B with a P/E ratio of 17.4x. The company generates $2.16B in trailing twelve-month revenue with a 7.7% profit margin.
Revenue growth is +15.9% quarter-over-quarter, while maintaining an operating margin of +13.2% and return on equity of +48.1%.
Valuation Metrics
Market Cap
$3.10B
Enterprise Value
$5.09B
P/E Ratio
17.4x
PEG Ratio
0.3x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+15.9%
Gross Margin
+26.1%
Operating Margin
+13.2%
Net Margin
+7.7%
EPS Growth
+61.2%
Financial Health
Cash/Price Ratio
+2.6%
Current Ratio
1.1x
Debt/Equity
500.6x
ROE
+48.1%
ROA
+8.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Concentra Group Holdings Parent Inc (CON) Business Model
About Concentra Group Holdings Parent Inc
What They Do
Provides healthcare and occupational health services.
Business Model
Concentra Group Holdings Inc. generates revenue by offering a range of medical services, including occupational medicine, urgent care, and physical therapy, primarily targeting employees of corporations and government entities. The company operates medical centers and on-site clinics to facilitate convenient access to healthcare, thus ensuring workforce health and productivity.
Additional Information
As a subsidiary of Select Medical Holdings Corporation, Concentra is positioned to adapt to changing healthcare demands, making it a significant player in the occupational health market, particularly in industries like manufacturing, transportation, and construction.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
9,967
CEO
Mr. William Keith Newton
Country
United States
IPO Year
N/A
Website
www.concentra.comConcentra Group Holdings Parent Inc (CON) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Concentra Group (CON) Q1 Earnings and Revenues Beat Estimates
Concentra (CON) delivered earnings and revenue surprises of +14.29% and +2.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2026
By Zacks Equity Research
Tale of the Tape
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of +35.71% and +12.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
CON vs. COR: Which Stock Is the Better Value Option?
CON vs. COR: Which Stock Is the Better Value Option?
May 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Concentra Group Holdings (NYSE: CON) reported double-digit revenue and adjusted EBITDA growth in Q1 2026, driven by higher workers' compensation visit volumes, acquisitions, and better cost control.
Why It Matters
Concentra's strong Q1 2026 growth signals robust operational performance, driven by increased visit volumes and acquisitions, enhancing its financial outlook and attractiveness as an investment.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Concentra Group Holdings Parent, Inc. (CON) held its Q1 2026 earnings call, providing insights into financial performance and strategic direction for investors.
Why It Matters
Earnings calls provide insights into a company's financial health, performance trends, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Concentra Group Holdings (NYSE: CON) reported strong Q1 2026 results, declared a cash dividend, and raised its full-year guidance, reflecting client trust in its occupational health services.
Why It Matters
Concentra's strong Q1 results and raised guidance indicate robust growth, enhancing investor confidence. The cash dividend signals financial health and commitment to shareholder returns.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Concentra Group (CON) reported quarterly earnings of $0.40 per share, exceeding the Zacks Consensus Estimate of $0.35, and up from $0.32 per share a year earlier.
Why It Matters
Concentra Group's earnings beat estimates and show year-over-year growth, indicating strong performance and potential for future gains, which can positively influence investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors are comparing Concentra Group (CON) and Cencora (COR) for potential value opportunities in the Medical Services sector.
Why It Matters
The comparison of Concentra Group and Cencora highlights potential investment opportunities in the Medical Services sector, influencing stock selection and portfolio strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Concentra Group Holdings Parent, Inc. (CON) Shareholder/Analyst Call Prepared Remarks Transcript
11 days ago
Quick Summary
Concentra Group Holdings Parent, Inc. (CON) held a shareholder/analyst call, discussing key company updates and financial performance. Further details were shared in the prepared remarks transcript.
Why It Matters
The call provides insights into Concentra's performance, strategy, and future outlook, influencing market sentiment and investment decisions regarding CON shares.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CON Stock
What is Concentra Group Holdings Parent Inc's (CON) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Concentra Group Holdings Parent Inc (CON) has a median price target of $30.00. The highest price target is $32.00 and the lowest is $28.00.
Is CON stock a good investment in 2026?
According to current analyst ratings, CON has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CON stock?
Wall Street analysts predict CON stock could reach $30.00 in the next 12 months. This represents a 24.2% increase from the current price of $24.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Concentra Group Holdings Parent Inc's business model?
Concentra Group Holdings Inc. generates revenue by offering a range of medical services, including occupational medicine, urgent care, and physical therapy, primarily targeting employees of corporations and government entities. The company operates medical centers and on-site clinics to facilitate convenient access to healthcare, thus ensuring workforce health and productivity.
What is the highest forecasted price for CON Concentra Group Holdings Parent Inc?
The highest price target for CON is $32.00 from Jamie Perse at Goldman Sachs, which represents a 32.5% increase from the current price of $24.16.
What is the lowest forecasted price for CON Concentra Group Holdings Parent Inc?
The lowest price target for CON is $28.00 from Stephen Baxter at Wells Fargo, which represents a 15.9% increase from the current price of $24.16.
What is the overall CON consensus from analysts for Concentra Group Holdings Parent Inc?
The overall analyst consensus for CON is bullish. Out of 10 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are CON stock price projections?
Stock price projections, including those for Concentra Group Holdings Parent Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 9:38 AM UTC